Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:TRX
- CUSIP: N/A
- Web: N/A
- Market Cap: £111.48 million
- Outstanding Shares: 743,183,000
- 50 Day Moving Avg: GBX 15.51
- 200 Day Moving Avg: GBX 17.73
- 52 Week Range: GBX 14 - GBX 22
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £1.2 million
- Price / Sales: 92.90
- Book Value: GBX 0.02 per share
- Price / Book: 7.50
- Average Volume: 113,912 shs.
Frequently Asked Questions for Tissue Regenix Group PLC (LON:TRX)
What is Tissue Regenix Group PLC's stock symbol?
Tissue Regenix Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "TRX."
Where is Tissue Regenix Group PLC's stock going? Where will Tissue Regenix Group PLC's stock price be in 2017?
2 equities research analysts have issued 1-year target prices for Tissue Regenix Group PLC's stock. Their forecasts range from GBX 39 to GBX 39. On average, they expect Tissue Regenix Group PLC's share price to reach GBX 39 in the next year. View Analyst Ratings for Tissue Regenix Group PLC.
Who are some of Tissue Regenix Group PLC's key competitors?
Some companies that are related to Tissue Regenix Group PLC include Mortgage Advice Bureau (Holdings) PLC (MAB1), Dotdigital Group plc (DOTD), Non-Standard Finance PLC (NSF), Arbuthnot Banking Group Plc (ARBB), Falcon Oil & Gas Ltd (FOG), McKay Securities plc (MCKS), Mothercare plc (MTC), Liontrust Asset Management PLC (LIO), Mattioli Woods plc (MTW), Mereo BioPharma Group PLC (MPH), Faron Pharmaceuticals Oy (FARN), Sportech plc (SPO), Exillon Energy Plc (EXI), Horizon Discovery Group PLC (HZD), Servelec Group PLC (SERV), IG Design Group PLC (IGR), Anglo Pacific Group plc (APF) and Microgen plc (MCGN).
Who are Tissue Regenix Group PLC's key executives?
Tissue Regenix Group PLC's management team includes the folowing people:
- John Samuel, Executive Chairman of the Board
How do I buy Tissue Regenix Group PLC stock?
Shares of Tissue Regenix Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Tissue Regenix Group PLC's stock price today?
MarketBeat Community Rating for Tissue Regenix Group PLC (LON TRX)MarketBeat's community ratings are surveys of what our community members think about Tissue Regenix Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Tissue Regenix Group PLC stock can currently be purchased for approximately GBX 15.
Consensus Ratings for Tissue Regenix Group PLC (LON:TRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 39|
Analysts' Ratings History for Tissue Regenix Group PLC (LON:TRX)
(Data available from 5/29/2015 forward)
|12/7/2016||Jefferies Group LLC||Lower Price Target||Buy||GBX 40 -> GBX 39|
|10/13/2016||Beaufort Securities||Reiterated Rating||Speculative Buy|
Earnings History for Tissue Regenix Group PLC (LON:TRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Tissue Regenix Group PLC (LON:TRX)
Current Year EPS Consensus Estimate: $-1.47 EPS
Dividend History for Tissue Regenix Group PLC (LON:TRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Tissue Regenix Group PLC (LON:TRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Tissue Regenix Group PLC (LON:TRX)
Latest Headlines for Tissue Regenix Group PLC (LON:TRX)
Tissue Regenix Group PLC (TRX) Chart for Monday, May, 29, 2017